Glaxosmithkline LLC

Smithkline Beecham Corporation

US Government As Represented by the Secretary of the Army

Anacor Pharmaceuticals, Inc.

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Jason Daniel Speake

Michael Joseph Bishop

David Lee Musso

David John Cowan

Andrew Lamont Larkin

Robert Toms Jacobs

Rodolfo Cadilla

Rustum S Boyce

Yang Liu

Jerzy Ryszard Szewczyk

Paul Kenneth Spearing

Richard J Sciotti

Gary Martin Green

Charles Eric Mowbray

Delphine Françoise Monique Launay

Stephen John Robinson

Gavin Alistair Whitlock

Paul Alan Glossop

Cunyu Zhang

Daniel T Chu

Aaron Matthew Smith

Stephen Andrew Thomson

David Richard Witty

David Harold Drewry

Frank Navas, Iii

Ronald George Sherrill

James G Phillips

Natalia Aurrecoechea

Anthony Louis Handlon

Douglas McCord Sammond

Andrew J Carpenter

Stephen J Hodson

Christopher R Conlee

Clifton Earl Hyman

Kien S Du

Brian D Thompson

Donald L Hertzog

Brian A Chauder

Joel P Cooper

Yu C Guo

Eric Cleveland Bigham

Deanna Trojan Garrison

Kevin Karl Barvian

Judith De Armas Kuntz

Kevin K Barvian

William R Swain

This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.

Oxaborole analogs and uses thereof

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction

Compounds as antagonists or inverse agonists at opioid receptors

The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.

Heterocycle compounds

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein. 

Substituted quinazolinone compounds

There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.

Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB. IA and IB have the following structures where Z has the formula shown below and the rest of the variables are defined herein 

Quinazolinone compounds with reduced bioaccumulation

A compound of formula (Ia) comprising a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided 

Pyrimidinones as melanin concentrating hormone receptor 1

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Growing community of inventors

Durham, NC, United States of America

Jason Daniel Speake